BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.

Trial Details

NCT ID
NCT04162353
Phase
PHASE1
Sponsor
iCell Gene Therapeutics
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • BCMA-CD19 cCAR T cells
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Signed written informed consent; Patients volunteer to participate in the research
  • Diagnosis is mainly based on the World Health Organization (WHO) 2008
  • Patients have exhausted standard therapeutic options
  • Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →